Bioscribe is a full-service communications consultancy focused on the life sciences sector. It provides custom communications programs for companies at various growth stages, offering services such as corporate communications, media strategy and public relations, social media management, content development, events organization, advocacy, and marketing communications. Bioscribe works with biotechnology and life science innovators.

Bioscribe

Bioscribe | 621 followers on LinkedIn. Let us help you tell your story. | Bioscribe was founded in 1997 in the San Francisco Bay Area to support the area&#39;s growing biotechnology industry. For more than two decades, we have worked with companies that powered the Human Genome Project and cutting-edge start-ups that are innovating to unlock its value. We&#39;ve helped launch first, second and third generation DNA sequencing systems, gene expression tools, bioinformatics software, single cell analysis solutions, molecular diagnostics, DNA forensics systems, next-generation therapies, and vaccines.

CEO of Bioscribe, Inc. - Life Sciences Communications Agency

Nicole Litchfield

Marketing and Communications

Andrew Noble

Strategic Healthcare Integrated Marketing Communications Executive | Public Relations | Global Media Relations Professional | Pharma & Biotech | Life…

Nancie Steinberg

Life Science Communications Consultant

Tim Ingersoll

Congratulations to the Vizgen team for securing the #1 private company spot on Genetic Engineering & Biotechnology News ' 2024 list of Top Spatial Biology Companies! Bioscribe is honored to partner with this innovative team and we are excited to support their continued success in 2025 and beyond! #InnovativeClients #ClientNews #PR #LifeScienceComms #LifesScienceMarketing #Biotech #LifeSciences

The trade media are often considered second fiddle to the buzzier top-tier outlets, but they are by no means less important to your overall earned media strategy. After 27 years working in the life sciences industry, the Bioscribe team has seen time and time again how this kind of targeted exposure is a perfect complement to the higher-profile articles placed in the top-tier media, allowing you to sustain momentum and credibility among key decision-makers and influencers. Read more about the 5 reasons why we believe that trade journalists, with their deeper understanding of the industry’s inner workings, can provide sophisticated and nuanced coverage that resonates with the often skeptical life science-focused audiences. #PR #MediaRelations #SciComms #BiotechPR #LifeSciencePR

Complex DNA is, in a word, complex. This excellent primer from Ansa co-founder & CSO, Dan Lin-Arlow, breaks it down and highlights how enzymatic DNA synthesis is paving the way forward for the complex DNA that is essential to driving innovation in the bioeconomy. #SynBioBeta2024 #InnovativeClients

PR tip: Don't forget to showcase your company's small wins between big milestones ⬇ Read more PR perspectives from Nicole Litchfield , CEO and founder of our partners at Bioscribe , in the latest issue of The Pitch: https://lnkd.in/gnyPWtiA

s2s Public Relations

Today we announced a partnership with s2s Public Relations , based in Seattle. From first working together on a co-marketing campaign seven years ago, to our new partnership announced today, it’s been a pleasure getting to know Eric Schudiske and his team. For more than 25 years, Bioscribe has been a trusted partner to the life sciences startup community, and advisor to founders, CEOs, VCs, commercial teams, and comms leaders who are shaping the future of innovation and the bioeconomy. We are excited about our new partnership with s2s because it broadens our bench with new talent and capabilities in ways that will benefit our individual and shared clients, as well as our teams! #teamwork #entrepreneurship #lifescience #scicomms #biotechPR

Thanks to Dani Stoltzfus and William Riedl at Mighty Spark Communications for hosting an engaging conversation with Bioscribe EVP Colin Sanford about when to consider the help of professional PR counsel. It's a question we get often, and one we are always happy to discuss. In a nutshell, the decision to enlist help extends beyond an approaching milestone. It's about strategically orchestrating your PR and communications programs to align with your near-term goals while fostering a platform for building and maintaining ongoing momentum for your long-term vision. If you're seeking support for the first time, or looking for ways to expand your existing PR and communications programs, please reach out for a free consultation. We'd be happy to share our perspectives on strategies that will help you successfully engage with all of your audiences today, and into the future. #biotechpr #lifesciencePR #scicomms #publicrelations #biotech

Big congratulations to the Synthego & EditCo teams on this industry-advancing milestone that will further accelerate innovation in the discovery and development of cell and gene therapies! #CRISPR #LifeSciences #Biotech #SciComm #CoolClients

Team Bonum Therapeutics has an incredible track record in biopharmaceutical dealmaking. In this insightful perspective, Chief Business Officer Neela Patel shares advice on navigating win-win negotiations that get you to the deal you want! #ThoughtLeadership #SmartClients

Congratulations to long-time Bioscribe client and friend Jason T. Gammack who has been appointed CEO of Ansa Biotechnologies, Inc. . Ansa is developing a new way to synthesize DNA that overcomes the limitations of traditional DNA synthesis methods to enable innovation across biologic therapeutics such as antibodies, gene therapies, and cell therapies, as well as the biomanufacturing of chemicals, materials, foods, and biofuels. https://lnkd.in/gQDUYqUu #CoolScience #AwesomeClients

In this Biocompare piece, client ATUM talks about how they leverage machine learning to power a directed engineering approach that enables them to determine the relationship between protein sequence and properties of interest and then use those insights to drive the engineering of improved variants. #biotech #proteinengineering #scienceiscool

news impact assignment basic	general
public peers	general	Nov 19, 2024 2:24 AM	cf89c066
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 19, 2024 2:24 AM	6688c21a
crunchbase trigger	general	Nov 19, 2024 2:24 AM	18906e5c
crunchbase profile	general
li profile	general	Nov 19, 2024 2:24 AM	10ac9311
translate crunchbase fundingrounds	general
peers	general	Nov 19, 2024 2:24 AM	a55a3d6a
news basic	general	Nov 19, 2024 2:24 AM	05b4b236
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

BIOS

COM:BIOSCRIBE

Bioscribe